If you are searching for the "open orphan share price" on your broker platform, you might notice that the old ticker symbol, ORPH, is no longer active. In late 2022, Open Orphan plc underwent a major strategic rebranding, officially changing its name to hVIVO plc and transitioning its stock ticker to HVO on the London Stock Exchange's Alternative Investment Market (AIM). Understanding the current value of this contract research organisation (CRO) requires looking past the legacy name and assessing how the restructured hVIVO plc is performing in today's financial landscape.
As of mid-2026, hVIVO's share price is trading in the range of 8p to 9.5p, stabilizing after a highly volatile couple of years. In this comprehensive guide, we will unpack the history of the open orphan share price, analyze the factors that drove its transition to hVIVO, evaluate its financial performance through the "biopharma winter" of 2025, and assess whether the stock presents a compelling value proposition for investors in 2026.
The Evolution: From Open Orphan to hVIVO plc
To understand the trajectory of the open orphan share price, one must first understand how the company evolved. Open Orphan plc was originally built through a series of strategic acquisitions orchestrated by Cathal Friel's Raglan Capital. The pivotal moment came in early 2020 when Open Orphan merged with hVIVO, a pioneer in human challenge clinical trials (HCTs).
The Strategic Rationale Behind the Rebrand
While Open Orphan operated as the parent company, its human challenge trial division, hVIVO, was globally recognized as the undisputed market leader in its niche. Human challenge trials involve the deliberate exposure of healthy volunteers to infectious agents (such as influenza, respiratory syncytial virus, or common cold viruses) in a highly controlled quarantine environment. This allows biopharma clients to quickly and cost-effectively test the efficacy of vaccines and antivirals.
In September 2022, the board announced plans to rebrand the entire Group as hVIVO plc, a change that took official effect on October 26, 2022. The rationale was simple: leverage the massive global brand equity of the hVIVO name within the biopharmaceutical industry. For shareholders, the transition was seamless. Existing shares in Open Orphan plc automatically converted to hVIVO plc shares on a 1:1 basis, the ISIN (GB00B9275X97) remained unchanged, and the ticker was retired in favor of HVO on the AIM and Euronext Growth markets.
The Poolbeg Pharma Spin-Out
Another critical event in the company's corporate history was the spin-out of Poolbeg Pharma plc (AIM: POLB) in July 2021. Poolbeg was established to commercialize a portfolio of clinical-stage asset developers, focusing on infectious diseases, which was spun out of Open Orphan. Shareholders of Open Orphan at the time received a direct distribution of Poolbeg shares. This corporate action is essential to keep in mind when analyzing long-term historical charts of the open orphan share price, as the distribution of assets naturally adjusted the parent company's market capitalization and per-share price.
Historical Performance: Tracking the Share Price Journey
The price chart of Open Orphan (now hVIVO) tells a story of rapid growth, pandemic-era speculation, macroeconomic headwinds, and a recent fundamental turnaround. Understanding these distinct phases is vital for any investor assessing the stock's current technical setup.
1. The COVID-19 and RSV Boom (2020–2021)
During the height of the COVID-19 pandemic, Open Orphan was thrust into the global spotlight. The company secured a landmark £10 million contract with the UK government to conduct the world's first COVID-19 human challenge characterisation study. This, combined with growing interest in respiratory syncytial virus (RSV) vaccines, sent the open orphan share price soaring. Speculative retail interest drove the stock to historic highs, peaking above 40p in mid-2021. However, like many pandemic-adjacent stocks, this valuation was unsustainable in the long term once the initial speculative wave subsided.
2. The hVIVO Transition and the 2024 Peak
Following the rebrand to hVIVO in late 2022, the company shifted its focus toward commercial execution and building a robust backlog of corporate contracts. Under the leadership of CEO Yamin 'Mo' Khan, the business expanded its quarantine facilities in London, establishing the world's largest purpose-built clinical trial quarantine site. This operational scaling bore fruit in late 2023 and throughout 2024, as the company repeatedly upgraded its financial guidance. By late 2024, hVIVO's share price climbed back toward the 30p mark, driven by robust profitability, contract wins, and a growing order book exceeding £70 million.
3. The "Biopharma Winter" and the 2025 Pullback
The year 2025 proved to be an exceptionally challenging period for the clinical research sector. A combination of factors dragged the share price down from its late 2024 peak to a low of approximately 4p to 7p in late 2025:
- Biotech Funding Winter: High interest rates globally led to a sharp contraction in venture capital funding for early-stage biotechnology firms. Because hVIVO relies on a mix of large-cap pharma and smaller, venture-backed biotechs, the broader sector slow-down resulted in delayed clinical program starts and highly cautious client spending.
- The RFK Jr. Effect: In late 2025, geopolitical and regulatory developments in the United States shook the healthcare market. The nomination of vaccine skeptic Robert F. Kennedy Jr. as US Health Secretary injected massive uncertainty into the biopharma sector. Vaccine development stocks and testing partners globally, including hVIVO, suffered from a sector-wide sell-off as investors fretted over future FDA approval processes and vaccine demand.
- Operational Delays: Several of hVIVO's scheduled trials faced minor delays due to volunteer recruitment bottlenecks and clinical scheduling, prompting a temporary dip in market sentiment.
4. The 2026 Recovery and Current Valuation
As we move through 2026, hVIVO's share price has staged a healthy recovery, ticking back up to the 8p to 9.5p range. This turnaround is supported by robust fundamental metrics and a clear demonstration that the company is outperforming its wider peer group. At current prices, hVIVO trades at a highly attractive price-to-sales (P/S) ratio of roughly 1.2x, which represents a steep discount compared to major US clinical research competitors such as Medpace Holdings, which often trade at P/S multiples above 4.5x. This valuation gap has captured the attention of value-focused small-cap fund managers.
Key Growth Drivers: Transforming into an End-to-End Partner
The recovery of the share price in 2026 is not merely a technical bounce; it is supported by a fundamental transformation of the business. Management recognized that being a pure-play human challenge trial (HCT) provider left the company vulnerable to volatility in infectious disease research budgets. Throughout 2025, they quietly executed a diversification strategy that has completely reshaped the firm's revenue profile.
Strategic Acquisitions of CRS and Cryostore
In 2025, hVIVO completed two highly strategic acquisitions that broadened its capabilities beyond HCTs:
- CRS (Clinical Research Services): Acquired in January 2025 for €10 million, CRS operates clinical sites in Mannheim and Kiel, Germany. It provides early-phase clinical trial services, including first-in-human and proof-of-concept studies. This acquisition added 120 beds of clinical capacity, allowing the group to capture traditional Phase I and Phase II trials.
- Cryostore: Acquired in February 2025 for up to £3.2 million, Cryostore is a specialized biobank and temperature-controlled logistics provider. It secures hVIVO's cold-chain infrastructure, ensuring that sensitive clinical trial samples can be safely stored and transported globally, while adding highly reliable, recurring subscription-like revenue to the group.
The April 2026 Unified Rebrand
In April 2026, hVIVO took the final logical step in its integration journey, consolidating its various operational subsidiaries—including Venn Life Sciences, CRS, and Cryostore—under a single, unified hVIVO corporate brand identity. This unification streamlines the sales pipeline, allowing a single sales team to pitch an end-to-end clinical development pathway, from preclinical consulting and biometry to specialized challenge trials, Phase I/II clinical testing, and biobanking. By removing internal silos, hVIVO has significantly reduced administrative overhead while aggressively cross-selling services to its existing tier-one biopharma clients.
Insider Buying Signals Confidence
One of the strongest signals of value for retail investors tracking the open orphan/hVIVO share price is insider ownership. In mid-December 2025, when the stock was heavily depressed by macro headwinds, CEO Yamin 'Mo' Khan and CFO Stephen Pinkerton stepped in to buy substantial amounts of stock. CEO Mo Khan purchased 3.3 million shares, and CFO Stephen Pinkerton also increased his holding. Such aggressive insider buying at multi-year lows serves as a powerful vote of confidence in the company's balance sheet and forward pipeline, helping to set a firm floor under the stock price.
Financial Analysis: Resilient Numbers in a Tough Climate
To understand why analysts are reiterating "Buy" and "Moderate Buy" ratings on the stock in mid-2026, we must look at the hard financial results. The full-year 2025 results, reported in April 2026, demonstrated remarkable financial resilience despite the macro-economic "biopharma winter".
| Financial Metric | FY2025 Result | Performance vs. Expectations |
|---|---|---|
| Revenue | ~£47.0 million | In line with market expectations |
| Adjusted EBITDA | >£1.0 million | Beat previous guidance of a small loss |
| Cash Balance | >£14.0 million | Highly robust capital cushion |
| 2026 Outlook | High single-digit growth | Re-iterated with confidence |
Analyzing the FY25 Beat
While many small-cap biotech and pharmaceutical services firms reported widening losses and dilutive emergency fundraises in 2025, hVIVO successfully stayed in the black. The company's revenue of nearly £47 million was flat-to-slightly-down compared to 2024, but its cost discipline was impeccable.
Crucially, hVIVO's commercial contracts contain robust cancellation and delay protections. When clients postponed studies in late 2025, hVIVO was able to collect significant postponement fees, which dropped directly to the bottom line. This allowed the company to post a positive adjusted EBITDA of over £1 million, completely beating analysts' fears of a small loss.
No Debt, Strong Cash
Perhaps the most compelling metric for risk-conscious investors is hVIVO's cash position. Ending 2025 with over £14 million in cash and zero debt means the company is fully funded for its organic growth plans. In the micro-cap and AIM-listed healthcare space, where dilutive share placements are an ongoing threat to retail investors, hVIVO stands out as an exception. The company even continues to pay a modest dividend (historically around 0.20p per share), a rarity for clinical service providers of this size.
Risks to the hVIVO Investment Case
While the turnaround story of hVIVO is compelling, no small-cap equity investment is without risk. Investors seeking to buy HVO shares should carefully weigh the following challenges:
- AIM Market Liquidity: The London Stock Exchange's Alternative Investment Market (AIM) is notorious for low liquidity and high volatility. Large bid-ask spreads can make it difficult to enter or exit positions quickly without impacting the stock price.
- Client Concentration: Although hVIVO boasts relationships with seven of the top ten global pharmaceutical companies, its revenue remains concentrated across a handful of high-value clinical contracts. A sudden cancellation of a major study, despite contract protections, can still create short-term revenue gaps.
- Political and Regulatory Headwinds: The ongoing regulatory shifts in the US healthcare landscape, particularly regarding the FDA's stance on clinical trial design and vaccine policy, can influence biopharma funding cycles and indirectly impact hVIVO's pipeline.
- Volunteer Recruitment: Human challenge trials depend heavily on the rapid recruitment of healthy volunteers (managed via hVIVO's FluCamp brand). Any bottleneck in recruitment can push trial timelines back, affecting quarterly revenue recognition.
Frequently Asked Questions (FAQs)
What happened to the Open Orphan share price?
The Open Orphan share price ticker (ORPH) was retired on October 26, 2022, when the company rebranded to hVIVO plc. If you held Open Orphan shares at the time, they were automatically converted into hVIVO plc shares under the ticker HVO on a 1:1 basis.
What is the current ticker symbol for Open Orphan?
The active ticker symbol is now HVO (listed on the London Stock Exchange AIM market). You can monitor the company's real-time performance and financial updates under hVIVO plc.
Is hVIVO (formerly Open Orphan) profitable?
Yes, hVIVO is a profitable business. Despite a very difficult macroeconomic environment in 2025, the company reported positive adjusted EBITDA of over £1 million for the full year 2025 and finished the year with over £14 million in cash and cash equivalents.
Why did Open Orphan rebrand to hVIVO?
The company rebranded to hVIVO plc to align its corporate identity with its most successful, globally recognized subsidiary. The hVIVO name has unmatched brand equity in the biopharmaceutical sector for human challenge clinical trials, making the rebrand logical for driving commercial growth.
What is the relationship between Open Orphan and Poolbeg Pharma?
Poolbeg Pharma plc (AIM: POLB) was a clinical-stage development business spun out of Open Orphan in July 2021. Open Orphan shareholders at the time received a direct distribution of Poolbeg shares, separating the asset development business from hVIVO's core services business.
Conclusion
The story of the open orphan share price is one of strategic evolution. By transitioning to hVIVO plc (HVO), the company successfully shed its complex conglomerate structure to become a streamlined, highly focused global leader in early-phase clinical development.
While the macro-driven sell-offs of 2025 hit the share price hard—dropping it into cheap penny-stock territory—the company's actions in 2026 show all the signs of a robust turnaround. With a unified end-to-end service offering, successful integration of key acquisitions like CRS and Cryostore, aggressive insider buying, and a cash-rich balance sheet, hVIVO plc appears well-positioned to reward patient investors as the biotech sector recovers. At current valuations, the former Open Orphan represents a highly resilient, cash-generative player trading at a significant discount to its global peers.
